Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Press release: Uppsala, May 31, 2023. In collaboration with Uppsala University and W. Szafer Institute of Botany, Dicot has investigated an alternative technology for future large-scale production of starting material for the company's drug candidate. The results show that the new technique involving plant cell cultures works on a laboratory scale.
In 2022 Dicot started a research project with Uppsala University and the W. Szafer Institute of Botany to investigate whether the starting material of the drug substance in LIB-01 can be produced by using plant cell cultures; an established technology for large scale commercial production of several drug substances from nature.
Today, the company notifies that the project has been successful in demonstrating that the technology works on a laboratory scale. Dicot will now proceed with the technology and carry out scale-up tests and optimization work to evaluate the technology on a larger scale and make comparisons with the existing process - where the starting material is extracted from natural plant material - that will continue simultaneously.
"These results open up a highly interesting alternative for future commercial production of our drug substance. Continued evaluation and scaling up of this technology is a responsible preparatory step for Dicot in line with our high ambitions with LIB-01", says Elin Trampe, CEO of Dicot.
For further information, please contact:
Elin Trampe, CEO
Phone: +46 739 80 14 08
E-mail: elin.trampe@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 4,100 shareholders. For more information, please visit www.dicot.se.
This disclosure contains information that Dicot AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 31-05-2023 13:46 CET.